ERBB2 and breast carcinoma: Genomic studies, including PAM50-based analyses, have highlighted molecular distinctions between HER2-low and HER2-zero tumors, raising the possibility that HER2-low breast cancer might represent a biologically unique subgroup within HER2-negative disease [11].